We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




A Circulating Adipokine Is a Possible Biomarker for Severity of Systemic Sclerosis-Associated Interstitial Lung Disease

By LabMedica International staff writers
Posted on 15 Aug 2021
A circulating adipokine (a cytokine chemical messenger produced by adipose tissue) has been identified as a possible biomarker associated with the severity of systemic sclerosis-associated interstitial lung disease.

While interstitial lung disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc), few predictive markers have been discovered, which can be used to assess progression of the disease. More...


Based on previous studies demonstrating that adipose tissue metabolism and adipokine homeostasis was dysregulated in Ssc, investigators at the University of Michigan (Ann Arbor, USA) sought to determine the association and predictive ability of the novel adipokine C1qTNF-Related Protein 9 for Ssc-ILD.

C1qTNF9, also known as CTRP9, is one of several adiponectin/Acrp30 paralogs which comprise the C1q and TNF-related protein family. All family members share a modular organization comprising a short variable region, a collagenous domain, and a C1q-like globular domain. CTRP9 is a 40 kiloDalton glycoprotein that contains multiple hydroxylated proline residues in its collagenous region. It circulates as a homotrimer and higher order multimers as well as in heterotrimers with adiponectin. It is preferentially expressed in adipose tissue and plays a role in glucose homeostasis.

For this retrospective study, the investigators analyzed data from 110 patients with interstitial lung disease and scleroderma. They determined serum levels of CTRP9 and collected clinical and lung function data every 12 months over a four-year period.

Results indicated that elevated circulating CTRP9 was associated with worse lung function, but that low CTRP9 levels identified patients with stability of lung disease with reasonable accuracy. These findings suggest that CTRP9 may be a potential biomarker in SSc-associated ILD.

“Despite interstitial lung disease being the leading cause of death among scleroderma patients, there are very few markers that predict progression of the disease,” said senior author Dr. John Vargar, chief of the division of rheumatology at the University of Michigan. “CTRP9 is an entirely novel biomarker that has never been implicated in scleroderma. It will help physicians predict the course of the disease and identify those patients who would not need to be on aggressive treatment for their lung disease.”

“The results from the new study add to the collection of biomarkers that could help for classification and treatment prediction for people living with scleroderma-associated lung disease,” said Dr. Varga. “We look forward to future studies that validate and expand upon this work.”

The study was published in the July 12, 2021, online edition of the journal Arthritis Care & Research.

Related Links:

University of Michigan


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR Setup
ESTREAM
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.